- Home
- CODA vs TLSA Comparison
CODA vs TLSA Comparison
Compare CODA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | TLSA |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 155.2M |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CODA | TLSA |
|---|---|---|
| Price | $11.87 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 371.4K | 140.5K |
| Earning Date | 03-17-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $148.63 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.76 | $0.73 |
| 52 Week High | $18.00 | $2.60 |
Technical Indicators
Market Signals| Indicator | CODA | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 44.96 |
| Support Level | $7.47 | N/A |
| Resistance Level | $12.22 | $1.62 |
| Average True Range (ATR) | 0.75 | 0.11 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 29.74 | 29.82 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.